MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
Healthcare
$1.98 +2.02%
+$0.08 today
- Market cap
- $126.54M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
52W Low $1.19High $4.64
Volume 0.93M
Average 0.98M
Income Statement
Follow revenue through to earnings.
Revenue
$149.50M
FY 2025 · Annual
+0.8% YoYOperating Income
-$72.84M
FY 2025 · Annual
Net Income
-$74.62M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| 59.94M | 61.41M | 61.93M | 62.62M | 63.16M | |
| 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MGNX Earnings Waterfall · TTM
NASDAQ:MGNX · Revenue to Net Income
Key Ratios
EPS$-1.10
Gross Margin62.6%
Net Margin-87.8%
P/E Ratio-0.5
P/S Ratio4.0
Analysis
$157.1M of revenue converted into -$70.4M of net income for the selected period. Gross margin is 62.6% and net margin is -87.8%, showing how much revenue survives after costs and taxes. EPS is $-1.10, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much revenue does MGNX generate?
MacroGenics, Inc. (MGNX) reported $149.50M of revenue in fiscal 2025.
Is MGNX profitable?
MacroGenics, Inc. (MGNX) reported -$74.62M of net income, with a net margin of -49.9%.
Continue the stock analysis
Jump to another research area for this company.